What Buyers Should Examine Before Acquiring a Pharma Business

 Acquiring a pharmaceutical business involves far more than reviewing its revenue, products and financial statements. Pharmaceutical companies operate within a highly regulated environment, where licences, product approvals, manufacturing standards, intellectual property and regulatory history can directly affect the value of the business.

A buyer may acquire a company with an attractive product portfolio but later discover unresolved regulatory issues, weak quality controls or restrictions on important intellectual property. Such issues can affect operations and create significant costs after completion.

Pharmaceutical M&A due diligence therefore needs to examine the legal, regulatory, commercial and operational position of the target. The objective is to understand what is being acquired, which risks may continue after completion and whether the business can maintain its operations under new ownership.

Review the Corporate Structure

The first step is understanding how the target business is legally organised. The buyer should examine the company's incorporation documents, shareholding, subsidiaries, joint ventures and ownership of important assets. It should also establish which entity conducts manufacturing, holds product approvals and enters into commercial contracts.

A group structure can contain several entities performing different functions. The buyer needs to understand how these entities interact and whether the proposed acquisition covers all relevant operations. Corporate records should also be reviewed for previous share transfers, investments and changes in control.

Examine Pharmaceutical Licences

Licences and approvals are central to a pharmaceutical business. The buyer should identify all licences required for manufacturing, distribution, storage, import, export and sale of pharmaceutical products. The relevant requirements depend on the nature of the business and the products involved.

India's Drugs and Cosmetics Act, 1940 and the rules made under it form an important part of the regulatory framework governing drugs and related activities. The Central Drugs Standard Control Organisation also performs regulatory functions relating to drugs and medical devices. 

Each relevant approval should be checked for validity, scope, renewal requirements and conditions. The buyer should also determine whether a change in ownership or control could affect any licence.

Investigate Product Approvals

A pharmaceutical company's value may depend heavily on its approved products. The buyer should establish which products are authorised for manufacture or sale and whether the approvals remain valid. The review should cover applications, approvals, variations, renewals, regulatory correspondence and restrictions.

Products under development should also be examined separately from products already approved. The buyer should understand the stage of each important product and identify regulatory milestones which may affect future commercialisation.

Review Manufacturing Facilities

Manufacturing operations require particular attention during diligence. The buyer should examine the facilities used by the target and determine whether the relevant permissions remain valid.

Quality systems, manufacturing processes, inspections and regulatory observations can also be important.The history of inspections should be reviewed carefully. Regulatory observations may indicate weaknesses in manufacturing or quality control. The buyer should also determine whether corrective actions have been completed.

Examine Good Manufacturing Practices

Pharmaceutical businesses must maintain appropriate quality standards. A buyer should examine the target's quality management systems, standard operating procedures and manufacturing records. Issues involving contamination, manufacturing deviations or inadequate quality controls can create significant regulatory and commercial risks.

The review should also consider whether the target has received warnings, notices or other regulatory communications concerning manufacturing standards. A history of repeated quality issues may require deeper investigation.

Check Product Recalls and Safety Issues

Product recalls can create substantial financial and reputational exposure. The buyer should examine current and historical recalls involving the target's products. The review should identify why a recall occurred, which products were affected and whether corrective measures were implemented.

Adverse event reporting and product safety information should also be considered where relevant. The purpose is not simply to identify previous recalls. It is to understand whether the underlying problem has been resolved.

Assess Regulatory Investigations

The buyer should identify ongoing and historical regulatory proceedings. These may involve drug regulators, competition authorities, consumer bodies or other government agencies. Regulatory notices should be reviewed alongside the target's responses.

An unresolved investigation may create continuing exposure after completion. The transaction documents may therefore need specific representations, warranties or indemnities concerning identified regulatory matters.

Examine Intellectual Property Ownership

Intellectual property can represent a major part of a pharmaceutical company's value. The target may own patents, trademarks, formulations, manufacturing processes, data and other proprietary rights.

The buyer should establish who owns each important asset. Patent portfolios should be reviewed for registration status, renewal requirements, remaining term and potential challenges. The buyer should also determine whether important technology is owned by the target or licensed from another party.

Review Patent Disputes

Pharmaceutical patent disputes can have a significant commercial impact. A challenge to a patent may affect the target's ability to maintain exclusivity over a product or manufacturing process. The buyer should therefore examine pending and threatened patent disputes.

It should also review previous litigation, settlement agreements and licensing arrangements. Restrictions arising from court orders or settlement terms should be identified before completion.

Examine Commercial Contracts

Pharmaceutical businesses often depend on extensive commercial arrangements. These may include agreements with distributors, suppliers, contract manufacturers, research organisations and healthcare institutions.

The buyer should review major contracts for duration, termination rights, assignment restrictions and change of control provisions. A transaction may require consent from a third party before a particular contract can continue. Failure to identify such provisions can create problems during or after completion.

Review Supply Chain Arrangements

Pharmaceutical companies depend on reliable supply chains. The buyer should understand where raw materials are sourced and whether critical ingredients depend on a limited number of suppliers. Long erm supply contracts should be reviewed for pricing, availability and termination rights.

The buyer should also examine whether regulatory requirements apply to suppliers or manufacturing partners. Supply chain weaknesses can affect production even when the target's own facilities remain compliant.

Examine Data and Clinical Information

Pharmaceutical businesses may hold extensive clinical, scientific and commercial information. The buyer should determine how such information is collected, stored and used. Where personal data is involved, the target's data protection practices should be reviewed. Clinical information can also have significant intellectual property and confidentiality implications. The buyer should therefore understand who owns the relevant data and whether it can be transferred or used after completion.

Review Employment and Key Personnel

Pharmaceutical companies may depend heavily on scientists, researchers, regulatory professionals and specialised technical employees. The buyer should identify key personnel and review their employment or consultancy arrangements.

Non compete provisions, confidentiality obligations and intellectual property clauses may also be relevant where legally enforceable. The departure of key personnel after an acquisition can affect research programmes and regulatory activities.

Examine Tax and Financial Liabilities

Financial due diligence remains important even in a highly regulated transaction. The buyer should examine revenue, debt, working capital, tax filings and outstanding liabilities. Tax disputes and contingent liabilities should also be identified.The financial review should be connected with the legal and regulatory review. A regulatory issue may create future costs which are not immediately visible in the company's accounts.

Assess Environmental and Waste Obligations

Pharmaceutical manufacturing can generate chemical and biological waste. The buyer should examine applicable environmental approvals, waste disposal arrangements and regulatory correspondence. Historical contamination or improper waste management can create remediation costs.Environmental liabilities should therefore be considered before the transaction is completed.

Competition Law Considerations

A pharmaceutical acquisition may also raise competition concerns. This can be particularly relevant where the buyer and target have overlapping products, markets or distribution channels. The Competition Commission of India regulates combinations falling within the statutory framework governing mergers and acquisitions. 

The parties should determine whether the proposed transaction requires notification or other regulatory action. Competition issues should be considered early because regulatory review can affect the transaction timetable.

Review Existing Litigation

The target's litigation history can reveal potential liabilities. The buyer should examine pending cases, threatened claims, settlements and regulatory proceedings. Pharmaceutical litigation can involve patents, product liability, contracts, employment and regulatory matters.

The buyer should also determine whether any dispute could affect a key product or licence. Where significant disputes exist, pharmaceutical attorneys for acquisitions can assist with assessing the regulatory and transactional implications before completion.

Understand Change of Control Consequences

Change of control provisions can affect pharmaceutical businesses in several ways. Contracts, licences, financing arrangements and joint ventures may contain restrictions triggered by a change in ownership. The buyer should identify these provisions early. If consent is required, the parties need to determine who will obtain it and whether the transaction can close without it.

Structure the Transaction Around Identified Risks

Due diligence findings can influence the structure of the acquisition. The buyer may negotiate specific warranties, indemnities, conditions precedent or escrow arrangements to address identified risks. For example, an unresolved regulatory investigation may require specific contractual protection. The appropriate mechanism depends on the nature and certainty of the risk.

What Happens When a Problem Is Found?

Not every diligence issue should stop an acquisition. Some problems can be corrected before completion. Others may require contractual protection or an adjustment to the transaction structure. The important consideration is understanding the potential impact. A buyer should distinguish between minor administrative gaps and issues which could affect the target's ability to manufacture, sell or distribute products.

Why Post Acquisition Compliance Matters

Due diligence does not end the buyer's responsibilities. After completion, the new owner may need to integrate compliance systems, update corporate records and maintain regulatory approvals. Changes to management or ownership should not disrupt regulatory responsibilities. A detailed integration plan can help ensure the target continues to comply with applicable requirements.

Litigation Risks After Completion

Some liabilities may only become apparent after the acquisition. A buyer may later discover undisclosed regulatory breaches, contract claims or product issues. The transaction documents become important in determining the parties' rights in such circumstances.

Where a dispute develops between the buyer and seller, litigation lawyers for business disputes may need to examine the acquisition agreement, disclosure materials and evidence concerning the underlying issue.

Conclusion

Acquiring a pharmaceutical business requires a detailed review of both commercial performance and regulatory exposure. Buyers should examine the corporate structure, licences, product approvals, manufacturing facilities, quality systems, recalls, regulatory investigations and intellectual property. They should also review contracts, supply chains, employment arrangements, data, tax liabilities, environmental obligations and litigation.

The central question is whether the buyer is acquiring a business capable of continuing its operations without unexpected regulatory or legal disruption. Thorough due diligence can help identify problems before completion and provide an opportunity to address them through remediation, transaction structuring or contractual protection.

For pharmaceutical acquisitions, regulatory compliance is not simply a supporting consideration. It can be closely connected with the value, continuity and future prospects of the business. A detailed review before completion can therefore provide a clearer understanding of both the opportunities and liabilities being acquired.